Publication Confidentiality. 7.1 Each party will keep and use the other party’s Confidential Information in confidence and will not, without the other party’s prior written consent, disclose the other party’s Confidential Information to any person or entity, except to the party’s directors, officers, employees, faculty, students and professional advisors who require the Confidential Information to assist such party in performing its obligations under this Agreement. The Licensee will maintain an appropriate internal program limiting the distribution of UBC’s Confidential Information to only those officers, employees and professional advisors who require such Confidential Information in performing the Licensee’s obligations under this Agreement and who have signed appropriate non-disclosure agreements.
7.2 Any party required by judicial or administrative process to disclose the other party’s Confidential Information, will promptly notify the other party and allow it reasonable time to oppose the process before disclosing the Confidential Information.
7.3 UBC is not restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals or other publications, accounts of its research relating to the Technology, provided that with respect to the Confidential Information only, the Licensee is provided with copies of the proposed disclosure at least 60 days before the presentation or publication date and does not, within 30 days after delivery of the proposed disclosure, give notice to UBC indicating that it objects to the proposed disclosure. Any objection to a proposed disclosure will specify the portions of the proposed disclosure considered objectionable (the “Objectionable Material”). On receiving notice from the Licensee that any proposed disclosure contains Objectionable Material, UBC will delay the proposed disclosure for 4 months from the date UBC delivered the proposed disclosure to the Licensee. After 4 months from the date UBC delivered the proposed disclosure to the Licensee, UBC is free to present and/or publish the proposed disclosure whether or not it contains Objectionable Material.
7.4 The Licensee and UBC agree that the terms and conditions of this Agreement are confidential, subject to disclosure requirements by applicable laws. Notwithstanding anything contained in Article 7, the Licensee and UBC agree that either party may identify the title of this Agreement, the parties to this Agreement and the names of the inventors of th...
Publication Confidentiality. 5.1 This Agreement shall not be interpreted to prevent or delay publication of Research findings resulting from the use of the Material or from its Modifications. RECIPIENT shall supply INSERM with a copy of all publication draft.
5.2 In accordance with scientific customs, the contributions of those who have made Material available or of collaborators, if any, from INSERM will be reflected expressly in all written or oral public disclosures concerning Research using the Material by acknowledgment or co-authorship, as appropriate. The origin of the Material and any applicable patent notices must be included in such disclosures.
5.3 Nothing however in this Agreement shall be construed as conferring rights to use in advertising, publicity, or otherwise the name of INSERM or INSERM-TRANSFERT or any of their marks.
5.4 RECIPIENT undertakes to respect and maintain strictly confidential all information identified as confidential received from INSERM Laboratory. RECIPIENT ensures that its personnel and any other persons in its service in any respect whatsoever respect and agree to respect the confidential nature of said confidential information. RECIPIENT undertakes to use confidential information only in the framework of the present Agreement.
Publication Confidentiality. 47 10.1 Notification................................................47 10.2 Review......................................................47 10.3
Publication Confidentiality. 7.1 Publication 7.2 Confidentiality; Exceptions.
Publication Confidentiality. 9.1 The Parties recognize that each may wish to publish the results of their work relating to the subject matter of this Agreement. However, the Parties also recognize the importance of acquiring patent protection. Consequently, subject to any applicable laws or regulations obligating any Party to do otherwise, any proposed publication by any Party shall comply with this Section 9. All publications, whether written or oral, shall be prepared in accordance with the joint publication strategy established and approved jointly by Argyll Biotech and Immunosyn. At least 45 days before a manuscript is to be submitted to a publisher, the publishing Party will provide the other Party with a copy of the manuscript. If the publishing Party wishes to make an oral presentation, it will provide the other Party with a summary of such presentation at least 30 days before such oral presentation and, if an abstract is to be published, 30 days before such abstract is to be submitted. Any oral presentation, including any question period, shall not include any Confidential Information (as defined below) unless the Parties otherwise mutually agree in writing in advance of such oral presentation.
9.2 Argyll Biotech and Immunosyn will each review the manuscript, abstract, text or any other material provided to it under Section 9.1 to determine whether patentable subject matter is disclosed. The non-publishing Party will notify the publishing Party within 30 days of receipt of the proposed publication if the non-publishing Party, in good faith, determines that patentable subject matter is or may be disclosed, or if, in good faith, it believes Confidential Information is or may be disclosed. If it is determined by the non-publishing Party that patent applications should be filed, the publishing Party shall delay its publication or presentation for a period not to exceed 60 days from the non-publishing Party’s receipt of the proposed publication or presentation to allow time for the filing of patent applications covering patentable subject matter. In the event that the delay needed to complete the filing of any necessary patent application will exceed the 60-day period, the Parties will discuss the need for obtaining an extension of the publication delay beyond the 60-day period. If it is determined in good faith that Confidential Information or proprietary information is being disclosed, the Parties will consult in good faith to arrive at an agreement on mutually acceptable modific...
Publication Confidentiality. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Publication Confidentiality. 5.1 This Agreement shall not be interpreted to prevent or delay publication of Research findings resulting from the use of the Material or from its Modifications. RECIPIENT shall supply INSERM and the Scientist Xx Xx Xxxx LONE with a copy of all publication draft.
5.2 In accordance with scientific customs, the contributions of the Scientist Xx Xx Xxxx LONE who have made Material available from INSERM will be reflected expressly in all written or oral public disclosures concerning Research using the Material by co-authorship, as appropriate. The origin of the Material and any applicable patent notices must be included in such disclosures.
5.3 Nothing however in this Agreement shall be construed as conferring rights to use in advertising, publicity, or otherwise the name of INSERM or INSERM-TRANSFERT or any of their marks.
5.4 RECIPIENT undertakes to respect and maintain strictly confidential all information identified as confidential received from INSERM Laboratory. RECIPIENT ensures that its personnel and any other persons in its service in any respect whatsoever respect and agree to respect the confidential nature of said confidential information. RECIPIENT undertakes to use confidential information only in the framework of the present Agreement.
Publication Confidentiality. 17.1 Purchaser shall have the right to make such public announcements or filings with respect to the acquisition as Purchaser may deem reasonably prudent. Purchaser shall not issue any such announcement without the prior approval of Seller as to the text of the announcement, not to be unreasonably withheld or delayed; provided, however, that Purchaser shall be entitled to make such filings or announcements upon advice of counsel as may be necessary or required.
17.2 Without the prior written consent of the other party, until Purchaser shall make a public announcement as provided in Section 17.1, neither Purchaser nor Seller shall disclose, and Seller and Purchaser will direct their respective representatives, employees, agents and consultants not to disclose, to any person or entity the fact that Purchaser and Seller have entered into an agreement to acquire the Property or any of the terms, conditions or other facts with respect to this Agreement. Notwithstanding the foregoing, either party may disclose those terms and conditions which are required to be disclosed pursuant to law or in order to comply with this Agreement; provided, however, that the disclosing party shall use its best efforts to limit the disclosure to the information necessary, shall advise any party to whom disclosure is made that said terms and conditions are subject to a confidentiality requirement and shall obtain the agreement of said party to keep any information disclosed to it as confidential. In the event of a breach of the provisions of this Section 17.2, either party shall be entitled to all of its rights and remedies at law or in equity.
Publication Confidentiality. 24 10.1 Notification......................................... 24 10.2 Review............................................... 24 10.3 Exclusions........................................... 25 10.4
Publication Confidentiality. (1) The parties shall concurrently coordinate the text of a publication and/or announcement relating to the takeover agreed herein. The disclosure of information to affiliated enterprises or advisers bound by their professional duty of secrecy shall remain unaffected by the obligation of such joint coordination.
(2) The parties agree that, subject to applicable securities law disclosure obligations, neither of them will disclose the terms of this Agreement without the prior written consent of the other, which consent will not be unreasonably withheld. However, both Gull and Fresenius may inform their employees regarding the existence of this Agreement.
